Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial

COMMENTED

Heart Failure

Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

★ 2 Recommended by Prof. Dr Isabella Sudano, Faculty Member

Lancet Diabetes Endocrinol

Davies MJ, van der Meer P, Verma S, Patel S, Chinnakondepalli KM, Borlaug BA, Butler J, Kitzman DW, Shah SJ, Harring S, Salsali A, Rasmussen S, von Lewinski D, Abhayaratna W, Petrie MC, Kosiborod MN, STEP-HFpEF Trials Committees and Investigators

doi: 10.1016/S2213-8587(24)00304-8

Heart, Artery and Coronary Diseases

Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial

Lancet

Fearon WF, Zimmermann FM, Ding VY, Takahashi K, Piroth Z, van Straten AHM, Szekely L, Davidavičius G, Kalinauskas G, Mansour S, Kharbanda R, Östlund-Papadogeorgos N, Aminian A, Oldroyd KG, Al-Attar N, Jagic N, Dambrink JE, Kala P, Angerås O, MacCarthy P, Wendler O, Casselman F, Witt N, Mavromatis K, Miner SES, Sarma J, Engstrøm T, Christiansen EH, Tonino PAL, Reardon MJ, Otsuki H, Kobayashi Y, Hlatky MA, Mahaffey KW, Desai M, Woo YJ, Yeung AC, Pijls NHJ, De Bruyne B

doi: 10.1016/S0140-6736(25)00505-7

Heart, Artery and Coronary Diseases

Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: rationale and design of a randomized controlled trial

Am Heart J

Haff N, Horn DM, Bhatkhande G, Sung M, Colling C, Wood W, Robertson T, Gaposchkin D, Simmons L, Yang J, Yeh J, Crum KL, Hanken KE, Lauffenburger JC, Choudhry NK

doi: 10.1016/j.ahj.2025.02.007

COMMENTED

Cardiovascular Risk and Diseases

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

★ 3 Recommended by Prof. Dr Isabella Sudano, Faculty Member

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

N Engl J Med

McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, Mann JFE, Emerson SS, Poulter NR, Engelmann MDM, Ripa MS, Hovingh GK, Brown-Frandsen K, Bain SC, Cavender MA, Gislum M, David JP, Buse JB, SOUL Study Group

doi: 10.1056/NEJMoa2501006

Cardiovascular Risk and Diseases

Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial

Lancet Diabetes Endocrinol

Aggarwal R, Bhatt DL, Szarek M, Cannon CP, Leiter LA, Inzucchi SE, Lopes RD, McGuire DK, Lewis JB, Riddle MC, Davies MJ, Banks P, Carroll AK, Scirica BM, Ray KK, Kosiborod MN, Cherney DZI, Udell JA, Verma S, Mason RP, Pitt B, Steg PG

doi: 10.1016/S2213-8587(24)00362-0

Cardiovascular Risk and Diseases

Improving 10-year cardiovascular risk prediction in patients with type 2 diabetes with metabolomics

Cardiovasc Diabetol

Xie R, Seum T, Sha S, Trares K, Holleczek B, Brenner H, Schöttker B

doi: 10.1186/s12933-025-02581-3

Cardiovascular Risk and Diseases

Bempedoic Acid Reduces the Risk of Major Adverse Cardiovascular Events Across Patient Subgroups

RECOMMENDED

Heart, Artery and Coronary Diseases

Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: A meta-analysis of 60 randomized controlled trials

★ 3 Recommended by Prof. Dr Isabella Sudano, Faculty Member

Atherosclerosis

Burger PM, Dorresteijn JAN, Koudstaal S, Holtrop J, Kastelein JJP, Jukema JW, Ridker PM, Mosterd A, Visseren FLJ

doi: 10.1016/j.atherosclerosis.2024.118540

Further Publications

Genetic Susceptibility to Type 2 Diabetes, Television Viewing, and Atherosclerotic Cardiovascular Disease Risk

J Am Heart Assoc

Wang M, Collings PJ, Day FR, Ong KK, Brage S, Sharp SJ, Jang H, Suh S, Luo S, Au Yeung SL, Kim Y

doi: 10.1161/JAHA.124.036811

Related content

Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial

Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial

Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: rationale and design of a randomized controlled trial

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial

Improving 10-year cardiovascular risk prediction in patients with type 2 diabetes with metabolomics

Bempedoic Acid Reduces the Risk of Major Adverse Cardiovascular Events Across Patient Subgroups

Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: A meta-analysis of 60 randomized controlled trials

Genetic Susceptibility to Type 2 Diabetes, Television Viewing, and Atherosclerotic Cardiovascular Disease Risk